Cargando…

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate (212)Pb-NNV003

Relapse of chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma after standard of care treatment is common and new therapies are needed. The targeted alpha therapy with (212)Pb-NNV003 presented in this study combines cytotoxic α-particles from (212)Pb, with the anti-CD37 antibody NNV003, targeti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maaland, Astri Fjelde, Saidi, Amal, Torgue, Julien, Heyerdahl, Helen, Stallons, Tania A. Rozgaja, Kolstad, Arne, Dahle, Jostein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080250/ https://www.ncbi.nlm.nih.gov/pubmed/32187209 http://dx.doi.org/10.1371/journal.pone.0230526

Ejemplares similares

Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate (177)Lu-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2019)

Anti-CD37 radioimmunotherapy with (177)Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro
por: Malenge, Marion M., et al.
Publicado: (2022)

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
por: Giesen, Danique, et al.
Publicado: (2022)

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2015)

Biodistribution and Dosimetry of (177)Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
por: Repetto-Llamazares, Ada H V, et al.
Publicado: (2013)

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab
por: Meredith, Ruby F., et al.
Publicado: (2018)

Demonstration of highly specific toxicity of the α-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
por: Aurlien, E, et al.
Publicado: (2000)

NNV Najaarsvergadering - Section Subatomic Physics
Publicado: (2013)

FDG PET/CT and Dosimetric Studies of (177)Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target?
por: Løndalen, Ayca, et al.
Publicado: (2022)

Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
por: Stokke, Caroline, et al.
Publicado: (2018)

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
por: Løndalen, Ayca, et al.
Publicado: (2020)

Toxicological Studies of (212)Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial
por: Milenic, Diane E., et al.
Publicado: (2015)

Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting (227)Th-DOTA-p-benzyl-trastuzumab
por: Heyerdahl, Helen, et al.
Publicado: (2012)

Ferritinaemia in Leukaemia and Hodgkin's Disease
por: Jones, P. A. E., et al.
Publicado: (1973)

Sites responsible for infectivity and antigenicity on nervous necrosis virus (NNV) appear to be distinct
por: Gye, Hyun Jung, et al.
Publicado: (2021)

Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET
por: Sharma, Sai Kiran, et al.
Publicado: (2021)

Experimental α-particle radioimmunotherapy of breast cancer using (227)Th-labeled p-benzyl-DOTA-trastuzumab
por: Abbas, Nasir, et al.
Publicado: (2011)

Chromosomes in Leukaemias Induces by S37 and Friend Viruses
por: Wakonig-Vaartaja, Resa
Publicado: (1961)

Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma
por: Hull, Ashleigh, et al.
Publicado: (2022)

NNvPDB: Neural Network based Protein Secondary Structure Prediction with PDB Validation
por: Sakthivel, Seethalakshmi, et al.
Publicado: (2015)

Differential Nervous Necrosis Virus (NNV) Replication in Five Putative Susceptible Cell Lines
por: Valero, Yulema, et al.
Publicado: (2021)

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate
por: Qu, C F, et al.
Publicado: (2004)

Indigenous versus Lessepsian Hosts: Nervous Necrosis Virus (NNV) in Eastern Mediterranean Sea Fish
por: Lampert, Yael, et al.
Publicado: (2020)

Nervous Necrosis Virus (NNV) Booster Vaccination Increases Senegalese Sole Survival and Enhances Immunoprotection
por: López-Vázquez, Carmen, et al.
Publicado: (2022)

Heritability of childhood leukaemia and non-Hodgkin lymphoma
por: Hawkins, M M, et al.
Publicado: (1996)

Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10q21.2
por: Studd, James B., et al.
Publicado: (2017)

Characterization of the Transcriptome and Gene Expression of Brain Tissue in Sevenband Grouper (Hyporthodus septemfasciatus) in Response to NNV Infection
por: Kim, Jong-Oh, et al.
Publicado: (2017)

NNV: The Neural Network Verification Tool for Deep Neural Networks and Learning-Enabled Cyber-Physical Systems
por: Tran, Hoang-Dung, et al.
Publicado: (2020)

Characterization of Nervous Necrosis Virus (NNV) Nonstructural Protein B2 and Its Enhancement on Virus Proliferation
por: Zhang, Yuqi, et al.
Publicado: (2022)

Synthesis and In Vivo Evaluation of a Site-specifically Labeled Radioimmunoconjugate for Dual-Modal (PET/NIRF) Imaging of MT1-MMP in Sarcomas
por: Pringle, Toni A., et al.
Publicado: (2022)

The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
por: Pichard, Alexandre, et al.
Publicado: (2019)

Author Correction: Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10q21.2
por: Studd, James B., et al.
Publicado: (2018)

Childhood leukaemia and non-Hodgkin's lymphoma in relation to proximity to railways
por: Dickinson, H O, et al.
Publicado: (2003)

Terminal deoxynucleotidyl transferase in hairy-cell leukaemia and Hodgkin's disease.
por: Srivastava, B. I., et al.
Publicado: (1978)

Cancer in the offspring of survivors of childhood leukaemia and non-Hodgkin lymphomas.
por: Hawkins, M. M., et al.
Publicado: (1995)

Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers.
por: Levi, F., et al.
Publicado: (1996)

Cancer in the offspring of survivors of childhood leukaemia and non-Hodgkin lymphomas.
por: Taylor, G. M.
Publicado: (1996)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Search of ligands suitable for (212)Pb/(212)Bi in vivo generators
por: Bartoś, Barbara, et al.
Publicado: (2012)

(177)Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice
por: Repetto-Llamazares, Ada H. V., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_a5dbkim95k4i09jeav85c7p7gr